Skip to content
November 17, 2026
  • Home
  • National News
    • Metro News
      • metro
    • Society
    • Politics
    • Crime and Justice
  • Special Reports
    • Investigation
    • Features
    • Interviews
  • Opinion
    • Business & Economy
    • Commentaries
    • Perspectives
  • Press Releases
  • International News
Political Economist

Political Economist

A liberal News reporting Politics, Sports, Business, Commentaries

  • Home
  • National News
    • Metro News
      • metro
    • Society
    • Politics
    • Crime and Justice
  • Special Reports
    • Investigation
    • Features
    • Interviews
  • Opinion
    • Business & Economy
    • Commentaries
    • Perspectives
  • Press Releases
  • International News
Watch Online
  • Home
  • International News
  • Roche arthritis drug can be prescribed for coronavirus patients
  • International News

Roche arthritis drug can be prescribed for coronavirus patients

Admin March 4, 2020
Korea

COVID-19

China will use a Roche Holding AG arthritis drug to treat some coronavirus patients in severe conditions, health authorities said on Wednesday, as the country seeks to build up treatment regimens to help the infected recover.

Tocilizumab, sold by the Swiss pharma giant under the trade name Actemra, can be prescribed to coronavirus patients who show serious lung damage and show elevated level of a protein called Interleukin 6, which could indicate inflammation or immunological diseases, the National Health Commission said in the latest version of its treatment guidelines published online.

Actemra can help contain inflammation related to Interleukin 6, according to Roche.

There is no clinical trial evidence yet that the drug will be effective on coronavirus patients, however. Actemra also has not received approval from China’s National Medical Product Administration to be sold for use for coronavirus infections.

Chinese researchers recently registered a 3-month clinical trial for Actemra that will recruit 188 coronavirus patients and take place from Feb. 10 to May 10, according to records shown on China’s clinical trials registration database.

Roche could not be immediately reached for comment. The firm said on Monday it donated 14 million yuan ($2.02 million) worth of Actemra during February.

The firm said in January it expects sales and profits growth this year as demand for new drugs and more business in China offsets declines in older medicines whose patents have expired.

Chinese drugmakers have been racing to develop alternatives to Roche’s treatment. Bio-Thera Solutions Ltd expects to file new drug approval for its Actemra biosimilar in 2021, and Zhejiang Hisun Pharmaceutical Co Ltd received in 2016 regulatory approval to conduct clinical trials for its Tocilizumab candidate, company filings showed.

Biosimilars are cheaper versions of complex biotech drugs such as Actemra.

  • Facebook
  • Share on X
  • LinkedIn
  • WhatsApp
  • Email
  • Copy Link
Tags: Actemra biosimilar Bio-Thera Solutions Ltd Swiss pharma Zhejiang Hisun Pharmaceutical Co Ltd

Post navigation

Previous Environmentalist lauds Delta State’s urban renewal programmes
Next Globally, more girls are going to school, staying in school than ever before – UNICEF

Related Stories

Microsoft outage hits Outlook, Teams and Copilot worldwide Microsoft
  • International News

Microsoft outage hits Outlook, Teams and Copilot worldwide

November 13, 2026
History in New Jersey: Nigerian-Born Lawyer Shirley Emehelu Sworn In as Lieutenant Governor
  • International News

History in New Jersey: Nigerian-Born Lawyer Shirley Emehelu Sworn In as Lieutenant Governor

November 11, 2026
Top 11 ‘Firsts’ about US midterm elections: First open gay, first black governor, others
  • International News

Top 11 ‘Firsts’ about US midterm elections: First open gay, first black governor, others

November 4, 2026
logo

Political Economist is a liberal news magazine with global affiliations.

At Political Economist, we promote free enterprise and act as a catalyst for the growth of knowledge economy. We are proudly pan-Nigeria yet richly spiced with African and global news. We offer a fair and balanced news reportage presented by our team of well-heeled professional journalists. <

About us

  • 5 Olutosin Ajayi Street, By CPM Church, Ajao Estate, Lagos State, Nigeria
  • +234 805 680 1124
  • info@politicaleconomistng.com

You may have missed

Nvidia says no way back for Huang despite support from Trump, Musk, others
  • Business & Economy

Nvidia says no way back for Huang despite support from Trump, Musk, others

November 17, 2026
Delta to spend 65% of N1.23trn 2027 budget on capital projects, allocates N320bn for roads
  • Business & Economy

Delta to spend 65% of N1.23trn 2027 budget on capital projects, allocates N320bn for roads

November 17, 2026
Lagos Assembly Urges Sanwo-Olu to Enforce Legislative Service Law, Passes Artisans Bill MDAs
  • metro

Lagos Assembly Urges Sanwo-Olu to Enforce Legislative Service Law, Passes Artisans Bill

November 16, 2026
Nigeria Secures Re-Election into ITU Council for 2027–2030 Term
  • National News

Nigeria Secures Re-Election into ITU Council for 2027–2030 Term

November 16, 2026
  • Home
  • National News
    • Metro News
      • metro
    • Society
    • Politics
    • Crime and Justice
  • Special Reports
    • Investigation
    • Features
    • Interviews
  • Opinion
    • Business & Economy
    • Commentaries
    • Perspectives
  • Press Releases
  • International News
Copyright © All rights reserved. | DarkNews by AF themes.